甲基尤根醇通过改善肺光滑肌肉细胞功能,缓解了高海拔肺高血压的老鼠的肺血管重塑
Yang Yu1, Yurong Wang1, Ziqi Yang1
1Department of Pharmacy, Qinghai University School of Medicine, Xining 810001, China.
概括
甲基尤根醇在治疗高海拔肺高血压方面表现有前途,通过减少肺动脉小动脉收缩和光滑肌肉细胞增殖. 这种化合物可以通过减少氧化应激和改善受影响的老鼠的心脏功能来缓解症状.
科学领域:
- 心血管研究研究心血管研究
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高海拔肺高血压 (HAPH) 是一种与缺氧相关的严重疾病,其特点是右心脏过载和潜在衰竭.
- 它的复杂病原包括氧化应激,线粒体功能障碍,亡和热亡.
- 当下降或氧气治疗不可行时,药理干预至关重要.
研究的目的:
- 在高海拔肺高血压的老鼠模型中研究甲基尤根醇的治疗潜力.
- 阐明甲基尤根醇影响肺血管收缩,光滑肌肉细胞增殖和氧化应激的机制.
主要方法:
- 在体外和体内实验中,使用HAPH.的老鼠模型进行了实验.
- 评估了甲基尤根醇对肺动脉狭窄,PASMC扩散,氧化应激标志物和心脏功能的影响.
- 通过Western blot分析了包括Nrf2/HO-1,HIF-1α和细胞循环调节器在内的关键分子通路.
主要成果:
- 甲基尤根醇通过减少活性氧物种和HIF-1α表达来缓解肺动脉收缩,并抑制PASMC的扩散.
- 在接受甲基尤根醇治疗的老鼠中,心脏缩功能和PASMC线粒体结构得到改善.
- 甲基尤根醇降低了氧化应激标志物 (MDA) 和增加了抗氧化剂水平 (SOD,谷氨),激活了Nrf2/HO-1通路.
结论:
- 甲基尤根醇在缓解肺血管收缩和HAPH中的血管改造方面显示出潜力.
- 该化合物的益处与减少氧化应激和抑制PASMC扩散有关.
- 这些发现为甲基尤根醇用于管理高海拔肺高血压提供了科学依据.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
118
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
118
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
151
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
151
01:30Pulmonary Hypertension: Classification and Pathogenesis
138
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
138
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
139
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
139
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
121
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
121
01:24Antiasthma Drugs: Methylxanthines
151
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
151